Bisfosfonater påverkar inte hörseln vid osteogenesis imperfecta. Retrospektiv studie av 42 journaler
Sammanfattning
The aim of this study was to follow a group of adult patients with osteogenesis imperfecta to see how their hearing changed with age, and if treatment with bisphosphonates affected their hearing. Osteogenesis imperfecta is a congenital genetic disease which causes osteoporosis and progressive hearing loss. Bisphosphonate treatment is a common therapy, with positive effects on bone density and fracture rate. Possible effects of bisphosphonates regarding hearing loss have not been thoroughly investigated. 36 adult patients with osteogenesis imperfecta underwent audiometry at two occasions. They were divided into two groups: one had received bisphosphonate therapy for at least three years between the two examinations, whereas the other group was untreated or treated for a shorter period. Hearing loss occurred in most patients, with an average yearly loss of 0.63 dB which is increased as compared to a normal control population. The hearing loss did not differ substantially between the two groups. Bisphosphonate treatment does not seem to significantly affect hearing in patients with osteogenesis imperfecta, with reservation for the duration of bisphosphonate treatment and the length of the study.